Research advances on nanozyme-based therapy for glioblastoma
CHEN Desheng
XIA Songsong
YANG Songyu
ZHAO Nannan
LI Ziyan
WANG Guangzhi
GUO Mian
Abstract：Glioblastoma(GBM)is the most common and highly malignant primary tumor of the central nervous system,characterized by high invasiveness,heterogeneity,and significant treatment resistance,leading to a dismal overall prognosis for patients.Conventional treatment modalities include surgical resection,radiotherapy,and temozolomide chemotherapy;however,their efficacy is severely compromised by factors such as the blood-brain barrier(BBB),abnormalities in the tumor microenvironment(TME),and enhanced antioxidant defenses in tumor cells.In recent years,nanozymes,nanomaterials with enzyme-like catalytic activity,have emerged as a research hotspot in GBM therapy due to their excellent stability,tunable catalytic properties,and multifunctional integration capabilities.Nanozymes can mimic the activities of peroxidase,oxidase,and catalase,generating reactive oxygen species(ROS)and disrupting intracellular homeostasis by depleting glutathione(GSH),alleviating hypoxia,and accelerating redox reaction rates,thereby inducing oxidative stress-related cell death.Some nanozymes exhibit significantly enhanced catalytic efficiency under exogenous stimuli such as ultrasound,light,or magnetic fields,synergizing with radiotherapy and chemotherapy.In the TME,nanozymes can also improve tumor permeability and sensitivity by denaturing collagen,remodeling the extracellular matrix,and modulating immune-related signaling pathways,while activating antitumor immune responses.Through surface functionalization and coupling with targeting molecules,nanozymes achieve trans-BBB delivery and tumor-selective localization.However,the clinical translation of nanozymes for GBM therapy still faces challenges such as long-term biosafety,insufficient delivery efficiency,individual variability,and standardization of synthesis processes.Overall,nanozymes offer novel and multidimensional therapeutic strategies for GBM treatment by catalytically modulating the TME and inducing multi-pathway cell death,holding promise for overcoming current therapeutic bottlenecks and improving patient outcomes.
Keywords：gliomaglioblastomananozymetumor microenvironmentreactive oxygen species
Publication Date：2026-01-20
Online Publishing Date：2026-02-07(First online date of this platform, not the publication date of the document)
Pages：7( 42-48 )